As of 2026-03-16, the Intrinsic Value of Amneal Pharmaceuticals Inc (AMRX) is 17.36 USD. This Amneal valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 11.83 USD, the upside of Amneal Pharmaceuticals Inc is 46.70%.
The range of the Intrinsic Value is 11.57 - 29.13 USD
Based on its market price of 11.83 USD and our intrinsic valuation, Amneal Pharmaceuticals Inc (AMRX) is undervalued by 46.70%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 11.57 - 29.13 | 17.36 | 46.7% |
| DCF (Growth 10y) | 18.68 - 41.27 | 26.17 | 121.2% |
| DCF (EBITDA 5y) | 14.50 - 18.43 | 16.54 | 39.8% |
| DCF (EBITDA 10y) | 20.66 - 27.27 | 23.93 | 102.2% |
| Fair Value | 1.15 - 1.15 | 1.15 | -90.31% |
| P/E | 3.69 - 12.60 | 8.36 | -29.3% |
| EV/EBITDA | 10.74 - 14.10 | 12.28 | 3.8% |
| EPV | 7.95 - 12.21 | 10.08 | -14.8% |
| DDM - Stable | 1.85 - 5.16 | 3.51 | -70.4% |
| DDM - Multi | 7.70 - 17.21 | 10.70 | -9.6% |
| Market Cap (mil) | 3,722.07 |
| Beta | 0.86 |
| Outstanding shares (mil) | 314.63 |
| Enterprise Value (mil) | 6,070.29 |
| Market risk premium | 4.60% |
| Cost of Equity | 8.55% |
| Cost of Debt | 8.24% |
| WACC | 7.68% |